2017 Emerging Science Program Schedule

The following is the schedule of Emerging Science abstracts to be presented at the 2017 AAN Annual Meeting. Abstracts qualify for Emerging Science presentations by having key aspects of research conducted after the October 24, 2016, abstract submission deadline and must be new and of sufficient scientific importance to warrant expedited presentation and publication. 

The Science Committee is committed to presenting the best neuroscientific research at the Annual Meeting, so we are excited to announce that we are presenting 21 abstracts as part of the Emerging Science program.

  • Tuesday, April 25: One abstract will be presented during the Clinical Trials Plenary Session from 9:15 a.m. to 11:00 a.m. Later that day, fourteen dual presentation abstracts will be featured in data blitz format during the first 45 minutes of the Emerging Science Platform session followed by poster presentations in the same room from 6:30 p.m. to 7:15 p.m.
  • Wednesday, April 26: Four poster presentations will be included in Poster Session IV from 8:30 a.m. to 7:00 p.m.
  • Thursday, April 27: Four poster presentations will be included in Poster Session V from 8:30 a.m. to 7:00 p.m.

The full 2017 Emerging Science abstracts are now available. If you have questions, please contact Renee Tessman, Senior Manager, Media and Public Relations.


Clinical Trials Plenary Session
9:15 a.m. to 11:30 a.m.

001 Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial
Peter Goadsby, MD, PhD, San Francisco, CA 

Emerging Science Platform Session
5:45 p.m. to 7:15 p.m.

001 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention: Primary Results of the ARISE Trial 
David W. Dodick, MD, FAAN, Phoenix, AZ

002 Non-invasive Vagus Nerve Stimulation for the Acute Treatment of Episodic and Chronic Cluster Headache: Findings from the Randomized, Double-blind, Sham-controlled ACT2 Study 
Peter Goadsby, MD, PhD, San Francisco, CA

003 Double-blind, Randomized, Placebo-controlled, Phase III Study (TOLEDO) to Evaluate the Efficacy of Apomorphine Subcutaneous Infusion in Reducing OFF Time in Parkinson's Disease Patients with Motor Fluctuations Not Well Controlled on Optimized Medical Treatment 
Regina Katzenschlager, MD, Vienna, Austria

004 Intraputaminal AADC Gene Therapy for Advanced Parkinson's Disease: Interim Results of a Phase 1b Trial 
Chadwick W. Christine, MD, San Francisco, CA

005 Motor Effects and Safety of IPX203, an Investigational Extended-release Formulation of Carbidopa-Levodopa, in Advanced Parkinson's Disease: A Single-dose Phase 2 Study 
Mark Stacy, MD, FAAN, Durham, NC

006 Results of a Phase 1 Study of ABBV-8E12 in Patients with Progressive Supranuclear Palsy and Phase 2 Study Design in Alzheimer's Disease and PSP 
Hana Florian, North Chicago, IL

007 Sustained Seizure Reduction with Adjunctive Everolimus for Treatment-refractory Seizures Associated with Tuberous Sclerosis Complex (TSC): Long-term Results from the Phase 3 EXIST-3 Study 
David N. Franz, MD, Cincinnati, OH

008 Cannabidiol (CBD) Significantly Reduces Drop Seizure Frequency in Lennox-Gastaut Syndrome (LGS): Results of a Dose-ranging, Multi-center, Randomized, Double-blind, Placebo-controlled trial (GWPCARE3) 
Anup D. Patel, MD, Columbus, OH

009 Efficacy and Safety of Nusinersen in Children with Later-onset Spinal Muscular Atrophy (SMA): Interim Results of the Phase 3 CHERISH Study 
Richard S. Finkel, MD, Orlando, FL

010 Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Multicenter Randomized Double-blind Placebo-controlled Trial: The PATH Study 
Ivo N. Van Schaik, MD, Amsterdam, Netherlands

011 Results of a Phase 1b/2 Study of ATYR1940 in Adult Patients with Limb Girdle Muscular Dystrophy Type 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) (ATYR1940-C-004) 
John Vissing, MD, Copenhagen, Denmark

012 Dual Responder Analyses of Both Muscle Strength and Activities of Daily Living, Eculizumab Versus Placebo, in Refractory Generalized Myasthenia Gravis (gMG) Patients: Results from the REGAIN Study 
James F. Howard, Jr., MD, FAAN, Chapel Hill, NC

013 Comparison of Protein-coding and Long, Non-coding RNA Gene Expression Signatures to Classify Multiple Sclerosis 
Charles Spurlock III, PhD, Nashville, TN

014 A 'Surface-in' Gradient of Thalamic Damage Is an Early and Disease-specific Process in Pediatric-onset Multiple Sclerosis 
Giulia Fadda, MD, Montreal, QC, Canada


Emerging Science Poster Presentations
Poster Session IV
8:30 a.m. to 7:00 p.m.

P4.406 Delayed-release Dimethyl Fumarate Reduces the Formation of T2 Lesions in Pediatric Patients with Relapsing-remitting MS: Results From FOCUS, the First Clinical Trial to Evaluate the Neuroradiological Efficacy of an MS Disease-modifying Therapy in Pediatric Patients 
Satish Eraly, MD, PhD, Cambridge, MA

P4.407 Patients Who Received Alemtuzumab in CARE-MS I or II Show a Low Rate of Conversion from Relapsing-remitting MS to Secondary Progressive MS Through 6 Years 
Dana Horakova, MD, PhD, Prague, Czech Republic

 Symptomatic and Objective Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with Autologous Epstein-Barr Virus-specific T Cell Therapy: Interim Results of a Phase I Trial 
Michael Pender, MD, PhD, Brisbane, Australia

P4.409 Radiological Evidence for the Long-Term Effect of Fingolimod Treatment in Patients with Relapsing-Remitting Multiple Sclerosis 
Jeffrey Allan Cohen, MD, Cleveland, OH


Poster Session V
8:30 a.m. to 7:00 p.m.

P5.409 3D Mathematical Modeling of Glioblastoma Suggests that Transdifferentiated Vascular Endothelial Cells Promote Resistance to Current Standard-of-care Therapy 
Daniela Bota, MD, Orange, CA

P5.410 Cholinesterase Inhibitor Use and Cognitive Decline in Mild Cognitive Impairment and Mild Dementia Due to Alzheimer Disease 
Jee-young Han, St. Louis, MO

P5.411 Seizures Are Locked to Long Time-scale Rhythms in Epilepsy 
Maxime Baud, MD, PhD, San Francisco, CA

P5.412 The Differential Effects of Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) Acids on Seizure Frequency in Patients with Drug-resistant Epilepsy-A Randomized, Double-blind, Placebo-controlled Trial 
Ahmed Daak, MD, PhD, Riviera Beach, FL


Forgot password?